Open archive
Clear filters
Showing 1-7 of 7 published briefings.
Company archive
Fisher & Paykel Healthcare (FPH) briefings
Read that company's published results in release order, newest first.
Fisher & Paykel Healthcare (FPH)FY26Released 26 May 2026
FPH capex nearly doubled to NZ$195.2m, compressing FCF conversion
Operating cash flow rose to NZ$663.2m and cash built to NZ$461.1m, but capex hit 8.5% of revenue and FCF/NPAT fell to 95.3%.
Published 26 May 2026
Read briefingFisher & Paykel Healthcare (FPH)HY26Released 26 November 2025
FPH PBT margin reached 26.1%, lifting profit 37.5% on 14.4% revenue growth
Operating leverage pushed margins above the recent historical range even as FCF conversion eased from 110.6% to 81.3% of NPAT.
Published 21 April 2026
Read briefingFisher & Paykel Healthcare (FPH)FY25Released 28 May 2025
Operating cash flow more than doubled to $548.6m as capex normalised
Revenue crossed $2.0bn for the first time and FCF reached 113.3% of NPAT, signalling earnings backed by cash after years of heavy capex.
Published 22 April 2026
Read briefingFisher & Paykel Healthcare (FPH)HY25Released 28 November 2024
FPH PBT up 46.8% as capex normalisation swings FCF positive
Operating leverage delivered above-baseline earnings growth while capex falling 80% to NZ$55.1m rebuilt FPH into a net cash position.
Published 22 April 2026
Read briefingFisher & Paykel Healthcare (FPH)HY24Released 29 November 2023
Capex doubled to 34.3% of revenue, pre-lease FCF swung to NZ$127.5m negative
Revenue grew 16.4% and PBT 23.0%, but a doubled capex bill drove pre-lease FCF NZ$258.5m below the historical mean and left the dividend uncovered.
Published 22 April 2026
Read briefingFisher & Paykel Healthcare (FPH)FY23Released 26 May 2023
FY23 FCF collapsed to $12.5m as capex stepped up 53%
H2 revenue rebounded 14%, but a 40.5c full-year dividend ran well past FCF cover with capex intensity climbing to 13.4% of revenue.
Published 22 April 2026
Read briefingFisher & Paykel Healthcare (FPH)HY23Released 29 November 2022
Working capital absorbed NZ$58.7m, draining operating cash to NZ$1.9m
Revenue fell 23.3% on post-COVID normalisation, but a NZ$58.7m working-capital build left the lifted dividend uncovered by free cash flow.
Published 22 April 2026
Read briefingGet reporting-season briefings
Get full NZX result briefings by email as new coverage is published.